Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo gets go-ahead for new infant products

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Perrigo's first new infant formula products since the Allegan, Mich., firm acquired PBM Holdings in March. Perrigo's partner, Quebec-based Kerry Proteins and Nutritionals, will manufacture the products, the private labeler said Aug. 23. The approved products include concentrate and ready-to-use milk-based infant formula with arachidonic and docosahexaenoic acids. The ready-to-use product also comes in an organic version. "This is the first launch of new products since acquiring our infant nutrition business and we look forward to further new product introductions," said CEO Joseph Papa. Collins Stewart analysts said the approvals allow Perrigo to produce store brands to compete with Abbott's Similac Advance and Mead Johnson's Enfamil Premium (1"The Tan Sheet" March 29, 2010)

You may also be interested in...

Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition

Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts